Editorials Hormone replacement therapy
Not long ago it was fashionable to argue whether treatment of postmenopausal women with oestrogens could cause cancer of the uterus. The correspondence columns of the New England Journal of Medicine, the Lancet and the British Medical Journal reverberated with letters from diverse workers who criticized any work (or workers) that attempted to show that the association of endometrial cancer and unopposed oestrogen therapy was anything more than fortuitous. As the tempo of debate increased, even writers of editorials on the subject became objects of criticism. Fortunately the debate can now cease -the data are in, they are hard and they make sense.
Eight papers published in the last four years have shown that treatment of postmenopausal women with unopposed oestrogens is associated with an increased risk of developing cancer of the uterus, and that the risk is related to the dose and the duration of treatment (for references see Hammond et al. 1979 Hammond et al. , lick et al. 1979 . The several studies have produced remarkably similar risk ratios, risk ratios that have survived independent re-evaluation of the original histopathological diagnoses (Gordon et al. 1977) . These estimates of the carcinogenic risk of oestrogen treatment were based on retrospective studies performed in the United States. Prospective clinical trials in this country have shown that the incidence of endometrial hyperplasia (the most severe form of which is considered to be a precursor of endometrial cancer) is directly related to the dose and duration of unopposed oestrogen therapy (Whitehead, McQueen et al. 1978) .
The data also make sense as we are beginning to develop an understanding of what underlies these events at the molecular level. While there is no room here for an extended discussion of the mechanism(s) of action of oestrogen, suffice it to say that ultimately the hormone acts by entering the cell nucleus and attaching itself on to the DNA and causing it to direct the synthesis of certain specific proteins. The synthesis of these proteins results in the changes we associate with the action of oestrogen. To enter the nucleus, oestrogens must first be bound and then transported by a specific protein that is found in the cytoplasm, the 0141-0768/79/110797-02/$01.00/0 oestrogen receptor protein. The amount of oestrogen that can enter the cell nucleus depends on the number of oestrogen receptors, their affinity for the various oestrogens and also on the stability of the complex formed with the particular oestrogen. Oestradiol 17p, the oestrogen secreted by the ovarian follicles of premenopausal women, is the most potent; oestrone is a weak oestrogen because it has a low affinity for the oestrogen receptor protein. Oestriol is even weaker because the complex it forms with the protein is retained in the nucleus for so short a time that the response it provokes is quite evanescent (Anderson et al. 1975) .
One of the advances in this field has been the realization that interconversion of steroids, and particularly of oestrone and oestradiol, occurs in several tissues. For instance, as described on page 839 by Hutton and his colleagues, when oestradiol is ingested the gut itself oxidizes it to oestrone, so plasma concentrations of oestrone and oestradiol are similar whether the women are treated with a preparation based on oestrone or on oestradiol. Curiously the vaginal epithelium lacks the necessary enzymes to effect this conversion and so when oestradiol is put directly into the vagina, plasma oestradiol concentrations are much higher than they are when it is given by mouth (Rigg et al. 1978) . This apparently obscure comer of biochemistry has important clinical consequences because it means that contraindications to systemic oestrogen therapy are now contraindications to local therapy too .
Oestradiol can also be converted in endometrial cells to the less potent oestrogen, oestrone. The rate of conversion is increased by progesterone, a hormone which, inter alia, induces activity of the enzyme that is responsible -oestradiol 17P dehydrogenase (Gurpide et al. 1976 ). In premenopausal women, activity of this enzyme is low in the follicular phase of the cycle, so the uterine endometrium grows at this stage (the proliferative phase). After ovulation the activity of the enzyme is stimulated by the progesterone secreted by the corpus luteum. Despite high blood levels of oestradiol during the luteal phase, the main oestrogen within the endometrial cell is therefore oestrone and, as this is only a weak oestrogen, continued proliferation of the endometrium does not occur. If progesterone is not secreted, as occurs during anovular menstrual cycles, endometrial hyperplasia may develop. In women with persistently anovular cycles, for instance those with the polycystic ovary syndrome, symptomatic endometrial hyperplasia and eventually endometrial cancer become significant risks (Lucas 1974) . It is likely that, in addition to stimulation of oestradiol l7B dehydrogenase, progesterone directly inhibits DNA directed synthesis of oestrogen receptor proteins. Progesterone thus has two actions that limit the impact of oestrogen on the endometrium.
It is a reasonable prediction from these studies of molecular biology that the addition of progesterone to treatment with oestrogen of postmenopausal women will reduce the incidence of endometrial hyperplasia and cancer. Studies from the United Kingdom (Thorn et al. 1979) and from the United States (Hammond et al, 1979) bear out these predictions. The results of Thorn and her colleagues show that the risks of oestrogen to the uterus can be abolished by concurrent treatment with progestogens. The smallest dose of oestrogen that will abolish climacteric symptoms, given cyclically, with the addition of a progestogen for 7 to 10 days of the cycle, is now the best way of administering postmenopausal oestrogen therapy.
What problems remain? Well, the obvious one is the anxiety that having abolished the risk of oestrogen to the uterus, we will replace it with the systemic risks of progestogens. Careful metabolic surveillance is therefore necessary. Should natural or synthetic oestrogens be used? At present no one can be certain because in those studies in which comparisons were made the doses, in terms of oestrogenic potency, were not comparable. Who should receive prolonged oestrogen therapy to avoid postmenopausal osteoporosis? Presumably the answer is, those who lose bone fastest. It is not yet certain, however, how to identify this group on a large enough scale to make selection a practicable possibility.
There is no doubt, however, that the greatest innovation that can be anticipated in the next few years will be the development of a nonsteroidal, nonoestrogenic treatment for postmenopausal flushing attacks. Most women develop this symptom, indeed it often comes on before the menopause and its course is quite unpredictable. Some women continue to have attacks well into their seventies. As Hutton et al. show (p 838), flushes do not seem to be related to specific hormone concentrations. The development of a simple treatment that does not involve giving oestrogens would represent a gigantic breakthrough for many climacteric women. HSJacobs
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